Under current conditions, pursuing development of a new cocaine pharmacotherapy via a typical full product development cycle is not economically viable from the standpoint of industry. Although a variety of hurdles or procedural impediments may affect prospects for new pharmacotherapy development in this area, most of these are regarded as surmountable by the industry. However, three critical market barriers to significant progress in bringing an effective pharmacotherapy to a viable market are:
- Small and uncertain market for cocaine addiction and abuse pharmacotherapy;
- A substance abuse treatment system that limits access to this market; and
- Limited and uncertain payment for pharmacotherapy for this indication.